Active	Status	Sponsor type	Region	Phase	Filter
6 Active 7 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Dreno, Brigitte
BECOME-MB, NCT04074096 / 2021-006331-26: Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis	Active, not recruiting	2	10	Europe	Stereotaxic radiosurgery (SRS), Binimetinib Oral Tablet, Mektovi, Encorafenib Oral Capsule, Braftovi, Pembrolizumab, Keytruda	UNICANCER, European Association of Dermato Oncology, Pierre Fabre Medicament, Merck Sharp & Dohme LLC	Malignant Melanoma, BRAF V600 Mutation, Brain Metastases	04/25	04/29
RIC-Mel, NCT03315468: French Clinical Datbase of Melanoma Patients	Recruiting	N/A	16000	Europe		Nantes University Hospital, CENGEPS, Bristol-Myers Squibb, Hoffmann-La Roche, GlaxoSmithKline, Amgen	Melanoma (Skin)	03/30	03/30